A range of selective and potent TDO, IDO1, and IDO2 inhibitors are currently under investigation in cancer research and information from this field may be translationally utilized for new personalized therapies for patients suffering from COVID-19 and PACS [52,86,296,297,298,299]. This evidence concerns the gene IDO2 and COVID-19.